PeerView | Genetics

Free CME from PeerView

Genetics CME

Credits: 2.0 CME / MOC

Purdue University

Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

Liana G. Apostolova, MS, MD, FAAN

March 18, 2022

Credits: 0.5 CME / NCPD

Medical Learning Institute, Inc.

Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy

Julie Parsons, MD

March 01, 2022

Credits: 0.5 CME

PVI, PeerView Institute for Medical Education

Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?

Herbert L. Bonkovsky, MD

February 25, 2022

PVI, PeerView Institute for Medical Education

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Neal K. Lakdawala, MD / Anjali Tiku Owens, MD

November 13, 2021

Medical Learning Institute, Inc.

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Lynette M. Sholl, MD

October 29, 2021

Medical Learning Institute, Inc.

On the Cusp of a New Targeted Treatment Era in ALS: Exploring the Emerging Therapeutic Landscape

Professor Dame Pamela J. Shaw

October 22, 2021

Heart Failure Society of America

Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

Daniel Jacoby, MD

October 01, 2021

Medical Learning Institute, Inc.

Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors

Susana Banerjee, MBBS, MA, FRCP, PhD

May 07, 2021

Medical Learning Institute, Inc.

Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

Karl E. Anderson, MD

April 15, 2021

Medical Learning Institute, Inc.

New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

March 09, 2021